Latest Ratios: P/E Ratio -0.4x · EV/EBITDA N/A · ROE -141.6%. (2015–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $9M | $22M | $3M | $4M | $241M | $15M | $908M | $165M | $476M | $1.4B | $493M |
| Enterprise Value | $-3809172517 | $-3796475185 | $-571643 | $2M | $238M | $8M | $909M | $160M | $471M | $1.4B | $491M |
| P/E Ratio → | -0.43 | — | — | — | — | — | — | — | 31.05 | 134.84 | 32.17 |
| P/S Ratio | — | — | — | — | — | — | — | — | — | — | — |
| P/B Ratio | 0.52 | 1.65 | 0.33 | 0.78 | 32.52 | 23.22 | — | 38.46 | 127.65 | 252.57 | 66.54 |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | 30.49 | 133.08 | 31.86 |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | 144.9% | — | 131.8% |
| Operating Margin | — | — | — | — | — | — | — | — | -5470.4% | — | -5470.4% |
| Net Profit Margin | — | — | — | — | — | — | — | — | -5470.4% | — | -5470.4% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -141.6% | -141.6% | -120.6% | -132.9% | -232.7% | -3266.6% | — | -38.9% | 334.6% | 158.5% | 303.3% |
| ROA | -87.6% | -87.6% | -64.3% | -65.2% | -78.8% | -399.9% | -55.5% | -26.7% | 214.6% | 115.9% | 250.2% |
| ROIC | — | — | -161.6% | -180.1% | — | — | — | — | 5290.2% | 210.2% | 307.2% |
| ROCE | -123.5% | -123.5% | -94.7% | -96.1% | -117.8% | -126.8% | — | -33.4% | 260.0% | 131.5% | 288.9% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | — | — | — | 0.07 | — | — | 0.00 |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | 0.00 |
| Net Debt / Equity | — | -291.02 | -0.39 | -0.42 | -0.39 | -11.39 | — | -1.15 | -1.28 | -0.73 | -0.22 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | -0.31 | -0.38 | -0.10 |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | -12.14 | -18.68 | -1.41 | -10.44 | — | — | — |
Net cash position: cash ($3.8B) exceeds total debt ($0)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.61 | 3.61 | 3.57 | 3.15 | 3.79 | 1.79 | 0.06 | 5.11 | 3.80 | 6.97 | 9.30 |
| Quick Ratio | 3.61 | 3.61 | 3.57 | 3.15 | 3.79 | 1.79 | 0.06 | 5.11 | 3.80 | 6.97 | 9.30 |
| Cash Ratio | 691.02 | 691.02 | 3.36 | 2.99 | 3.64 | 1.64 | 0.04 | 4.98 | 3.64 | 6.77 | 8.88 |
| Asset Turnover | — | — | — | — | — | — | — | — | -0.05 | — | -0.03 |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | — | -75.35 | — | -224.22 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | 27.1% | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | 3.2% | 0.7% | 3.1% |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 6.2% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 33.2% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $1M | $133964 | $25741 | $403883 | $1597 | $20024 | $3544 | $2157 | $1866 | $1518 |
Clinical trial funding dependency
Based on the provided financial data, QNRX trades at a price-to-book ratio of 0.51, which, according to recent market observations, suggests that investors are heavily discounting the company's asset base due to the high probability of future equity dilution required to fund ongoing clinical development.
The negative P/E ratio of -0.42 is typical for a pre-revenue biotech, yet the low P/B multiple indicates that the market assigns little value to the company's current intellectual property or pipeline assets. This valuation appears to reflect a deep skepticism regarding the commercial viability of the Invisicare platform, or perhaps a reaction to the historical pattern of reverse stock splits.
As reported in financial statements, the company's ROIC reached -190.5% in 2025Q2, illustrating that the firm is currently destroying invested capital at an accelerating rate as it attempts to advance its lead clinical candidates through the regulatory pipeline without any offsetting revenue generation.
The persistent negative ROE and ROIC trends underscore the fundamental challenge of a clinical-stage firm that lacks a commercial product to generate returns. Investors should monitor whether the company can achieve a pivot toward positive returns on capital, though this appears unlikely until at least one asset reaches the commercialization phase.
According to quarterly filings, the current ratio of 2.87 in 2026Q1 suggests a superficial level of liquidity, yet this metric is misleading given the company's lack of revenue and the high, non-discretionary cash burn required to maintain clinical trial sites and regulatory compliance.
While the quick ratio matches the current ratio, indicating no inventory dependence, the absolute cash levels remain insufficient to support long-term operations. The liquidity position appears vulnerable to any unexpected delays in clinical milestones, which would necessitate immediate and potentially dilutive capital raises to maintain the firm's going-concern status.
Based on an analysis of the firm's financial structure, the current ratio is the most commonly misapplied metric for QNRX, as it obscures the reality that the company's current assets are primarily cash being consumed by R&D rather than working capital supporting a revenue-generating cycle.
Analysts should instead focus on the 'cash runway'—the number of quarters the company can survive at current burn rates—rather than traditional liquidity ratios. Relying on the current ratio may lead to a false sense of security, as it fails to account for the binary nature of clinical-stage biotech funding requirements.
Includes 30+ ratios · 11 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying QNRX stock.
Quoin Pharmaceuticals, Ltd.'s current P/E ratio is -0.4x. The historical average is 66.0x.
Quoin Pharmaceuticals, Ltd.'s return on equity (ROE) is -141.6%. The historical average is 3.6%.
Based on historical data, Quoin Pharmaceuticals, Ltd. is trading at a P/E of -0.4x. Compare with industry peers and growth rates for a complete picture.